Breakthrough Clinical Trial to be featured on CNN: Reductions in Suicidality, Depression, and Post-Traumatic Stress
MISSION VIEJO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. ("MYnd") (OTCQB:MYAN), announces publication of “The Use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to Personalize Pharmacotherapy” by the Journal of Neuropsychiatric Disease and Treatment. The publication will be featured on “The Lead” with Jake Tapper, airing on CNN on Veteran’s Day, November 11, 2016.
In the randomized, controlled, double blind trial, doctors used either “treatment as usual” or MYnd Analytics’ PEER Interactive to determine a course of treatment based on a patient’s brain function. PEER Interactive uses algorithms and a database, consisting of outcomes from more than 10,000 individuals, to generate an objective report which can help a physician select an appropriate mental health medication for an individual as opposed to “treatment as usual” which involves a significant degree of trial and error.
In this study service members whose doctors followed a machine learning treatment recommendation in their selection of medications experienced significant improvement in their mental health conditions: depression scores improved by 144%, post-traumatic stress disorder (PTSD) scores improved by 139%, and suicidal ideation was reduced by 75% when compared with patients whose doctors did not follow the PEER Interactive recommendations.
Clinical Trial Demonstrates Improvement in Depression, Suicidality, and Post Traumatic Stress is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/eabba10f-c773-450a-90c5-2eabfbb33f73
“The best way we can honor veterans is to make sure that their treatments work,” said George Carpenter, CEO of MYnd Analytics. “Every patient deserves access to objective, evidence-based, personalized treatments. We brought PEER to the military first because we believed it could help doctors save lives.”
The study was the fourth scientific replication of previous studies, all of which demonstrated the efficacy of PEER technology in improving patient outcomes. An additional replication study has started with Canadian Forces and a further study of veterans is forthcoming in the United States. PEER Interactive is a predictive medicine technology developed by MYnd Analytics, Inc. (OTCQB:MYAN), which combines an EEG scan of brain function with a registry of long-term outcomes for over 10,000 psychiatric patients.
The full study, “The Use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to Personalize Pharmacotherapy” has been published by the Journal of Neuropsychiatric Disease and Treatment and can be read online.
The study’s authors are:
- Dan V. Iosifescu, M.D., MSc, Director, Adult Psychopharmacology Program, Associate Professor of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai
- Robert J. Neborsky, M.D., Clinical Professor of Psychiatry, School of Medicine, University of California, San Diego, CA, (Hon) Clinical Professor, University of California, Los Angeles, CA, Former Lieutenant Commander, Medical Corps, US Navy
- Robert Valuck, Ph.D., R.Ph., Professor of Pharmacy, Epidemiology, and Family Medicine, University of Colorado, Denver, CO, Director, Center for Pharmaceutical Outcomes Research, University of Colorado, Denver, CO, President, Board of Directors, Colorado Prescription Drug Abuse Task Force, Denver, CO, Professor (adjoint), Department of Epidemiology, Colorado School of Public Health, Denver, CO
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) provides a unique set of reference data and analytic tools for clinicians and researchers in psychiatry. While treatment for mental disorders has doubled in the last 20 years, it is estimated that 17 million Americans have failed two or more medication therapies for their mental disorders. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Media Contact: Lauren Jenkins ScoutComms (202) 596-5669
Released November 10, 2016